ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
Psilocybin therapy is effective for treatment-resistant depression
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 232264" data-attributes="member: 3"><p>This is only a partial list of companies racing to get a product approved:</p><p></p><p><strong>PharmAla Biotech</strong> ($MDMA) filed a patent application for 6 MDMA analogs and has been selected as the MDMA manufacturing partner for The University of Sydney's upcoming Phase II clinical trial. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-y/" target="_blank">Details</a></p><p style="text-align: center"><img src="https://ci4.googleusercontent.com/proxy/rGWBborI0k52_MsDZJy_RaNN-mdYO9kn8nF6Ja59CQjaAPx9KFd1-OjG2_wxWCP64E46Mz2WTifUYp7kLgI7g1kHdZKwTziWIRGyQiKyIswnBOFpnKcL_VIv8dvs7giuPWGuOo1MKrAejAwXMtDmbA0YGr31Gg8=s0-d-e1-ft#http://i6.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci4.googleusercontent.com/proxy/rGWBborI0k52_MsDZJy_RaNN-mdYO9kn8nF6Ja59CQjaAPx9KFd1-OjG2_wxWCP64E46Mz2WTifUYp7kLgI7g1kHdZKwTziWIRGyQiKyIswnBOFpnKcL_VIv8dvs7giuPWGuOo1MKrAejAwXMtDmbA0YGr31Gg8=s0-d-e1-ft#http://i6.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Cybin</strong> ($CYBN) announced first patient dosing in their Phase I/IIa trial evaluating CYB003, a proprietary deuterated psilocybin analog, as a potential treatment for major depressive disorder. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-j/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci3.googleusercontent.com/proxy/wCR1TsLXduH1tN1BaBgyxyHPEMrmsVEZOYY5J4zQHv8Y_MwdNGaM7i0YXsVg_Xh8Ozq4-e8yFKzEkf5cC_EYPItWUQbJGt_tPBBF875WK77xVGRiDvqfDGk9OpZoJ20qbrsXKTXn6YkGMb0TJoVHBRB2u_1Qo-g=s0-d-e1-ft#http://i7.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci3.googleusercontent.com/proxy/wCR1TsLXduH1tN1BaBgyxyHPEMrmsVEZOYY5J4zQHv8Y_MwdNGaM7i0YXsVg_Xh8Ozq4-e8yFKzEkf5cC_EYPItWUQbJGt_tPBBF875WK77xVGRiDvqfDGk9OpZoJ20qbrsXKTXn6YkGMb0TJoVHBRB2u_1Qo-g=s0-d-e1-ft#http://i7.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Lobe Sciences</strong> ($LOBE | $LOBEF) entered into an investment agreement with Cantheon Capital to fund $1.5M USD toward clinical trials in Australia. Lobe Sciences will conduct three clinical trials evaluating their proprietary psilocin analogues. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-t/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci6.googleusercontent.com/proxy/8qHKmKFT2gxFpCbcYiz0CUAMvQQAtW-7qzKtjEBcLp51A4GdxadI3xkh5bCxCmaawDssLLSngjkAYfRYXdXT-0pVjDfvZQvbaIdBIvMWTES14MKVCFbiN2V0htcgubCSOb3XUyM49gcQrAbev_PsyMkDvku1nro=s0-d-e1-ft#http://i8.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci6.googleusercontent.com/proxy/8qHKmKFT2gxFpCbcYiz0CUAMvQQAtW-7qzKtjEBcLp51A4GdxadI3xkh5bCxCmaawDssLLSngjkAYfRYXdXT-0pVjDfvZQvbaIdBIvMWTES14MKVCFbiN2V0htcgubCSOb3XUyM49gcQrAbev_PsyMkDvku1nro=s0-d-e1-ft#http://i8.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Optimi Health</strong> ($OPTI | $OPTHF) entered into an international psilocybin supply agreement with Promises Innovative Recovery, a research and educational center focused on innovative treatments with psychedelic-assisted psychotherapy. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-i/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci4.googleusercontent.com/proxy/n-vzdQxYgBoGkhwCYpxLNJcwW8pXYBBuyGcNWPl-hP9fXyqE3nGz8E0f78EpXBz-nvjp994pxFyEm5XnS2QKYCeCI4OBJuPFxS5omLOTm0qc_Rn0Z4uMSLWHyBrZaVDcXdHRqI9LWRhTW4u1z3jQdXF-SU7GJ-U=s0-d-e1-ft#http://i9.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci4.googleusercontent.com/proxy/n-vzdQxYgBoGkhwCYpxLNJcwW8pXYBBuyGcNWPl-hP9fXyqE3nGz8E0f78EpXBz-nvjp994pxFyEm5XnS2QKYCeCI4OBJuPFxS5omLOTm0qc_Rn0Z4uMSLWHyBrZaVDcXdHRqI9LWRhTW4u1z3jQdXF-SU7GJ-U=s0-d-e1-ft#http://i9.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Filament Health</strong> ($FH | $FLHLF) began dosing patients with their natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA Journey Centers' psychedelic-assisted therapist training program. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-d/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci3.googleusercontent.com/proxy/ViDe4d4DPnjpV4QKzLYZZiJyJziHnnd8YZXlZfKgqb1XcrR7YznxZTd-tUJw9lc9YPTa4oKmRpoCFP11D9123CcPYDGCVfr9b6o7XElOFvx5cU2dp0_neGWVOe3cTHARiAgVqh_TbTGQjsFYYFwLJD14V-rTZvAC=s0-d-e1-ft#http://i10.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci3.googleusercontent.com/proxy/ViDe4d4DPnjpV4QKzLYZZiJyJziHnnd8YZXlZfKgqb1XcrR7YznxZTd-tUJw9lc9YPTa4oKmRpoCFP11D9123CcPYDGCVfr9b6o7XElOFvx5cU2dp0_neGWVOe3cTHARiAgVqh_TbTGQjsFYYFwLJD14V-rTZvAC=s0-d-e1-ft#http://i10.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Mindset Pharma</strong> ($MSET | $MSSTF) identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds, further expanding their IP portfolio. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-h/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci6.googleusercontent.com/proxy/u0p8VGgBDzEFwZh5VF6Ry0LdfGjxFOj5DKNWeWjK0XrN_1BwcEoJ6j121dEjjD5ZqVnIPZ2ZEMFoYJhAWWhCgQl5XoyLa_24PEPlTJkE_rKTt9jmA4F7XqSo95tV2JSYJ4NS1X6GBhYeUFQYsHRyInf-rjR2SCU=s0-d-e1-ft#http://i1.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci6.googleusercontent.com/proxy/u0p8VGgBDzEFwZh5VF6Ry0LdfGjxFOj5DKNWeWjK0XrN_1BwcEoJ6j121dEjjD5ZqVnIPZ2ZEMFoYJhAWWhCgQl5XoyLa_24PEPlTJkE_rKTt9jmA4F7XqSo95tV2JSYJ4NS1X6GBhYeUFQYsHRyInf-rjR2SCU=s0-d-e1-ft#http://i1.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Core One Labs</strong> ($COOL | $CLABF) initiated rollout of their commercial sales strategy for their proprietary biosynthetic API psilocybin product. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-k/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci6.googleusercontent.com/proxy/Y8hSoxVJyUeR1G9PbXXkiTicdoMPTSnFrpyz4cvpKpIDNV99eBiCL1jRvlJ9sBpdJWqSS_Euof81Fa21Kq8Vv063CegikJ9o73Sqt1p4t5kZuOX-WEhmx2uubcqLqGdav6w6L4C6nY14RMJ0mjLVpP4Dlc_qbu8=s0-d-e1-ft#http://i2.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci6.googleusercontent.com/proxy/Y8hSoxVJyUeR1G9PbXXkiTicdoMPTSnFrpyz4cvpKpIDNV99eBiCL1jRvlJ9sBpdJWqSS_Euof81Fa21Kq8Vv063CegikJ9o73Sqt1p4t5kZuOX-WEhmx2uubcqLqGdav6w6L4C6nY14RMJ0mjLVpP4Dlc_qbu8=s0-d-e1-ft#http://i2.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Wesana</strong> <strong>Health </strong>($WESA | $WSNAF) announced the sale of their clinic management assets for USD$2,100,000 as part of an effort to strengthen their balance sheet and streamline the company. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-u/" target="_blank">Press Release</a></p><p style="text-align: center"><img src="https://ci4.googleusercontent.com/proxy/vKk6jzatrDgGyml5QYVy9bMSbLVUu62n3nTg4zNM9evMrBPdg9zKnCyaPOQ0c3CKV4nHVQY8_7QZQwmY3jjlcttdU5-5cIkAHHSEedFm5hjDGEz0T_esWl50tqhdNKXhSGnId1yK68yLuYGzkJm_iT2IqQpg_ho=s0-d-e1-ft#http://i3.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" class="bbImage" alt="" data-url="https://ci4.googleusercontent.com/proxy/vKk6jzatrDgGyml5QYVy9bMSbLVUu62n3nTg4zNM9evMrBPdg9zKnCyaPOQ0c3CKV4nHVQY8_7QZQwmY3jjlcttdU5-5cIkAHHSEedFm5hjDGEz0T_esWl50tqhdNKXhSGnId1yK68yLuYGzkJm_iT2IqQpg_ho=s0-d-e1-ft#http://i3.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png" style="" /></p><p><strong>Mydecine Innovations </strong>($MYCO | $MYCOF) signed a LOI to sell its wholly-owned subsidiary, Mindleap Health, to PanGenomic Health for a purchase price of C$4,000,000. <a href="https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-o/" target="_blank">Press Release</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 232264, member: 3"] This is only a partial list of companies racing to get a product approved: [B]PharmAla Biotech[/B] ($MDMA) filed a patent application for 6 MDMA analogs and has been selected as the MDMA manufacturing partner for The University of Sydney's upcoming Phase II clinical trial. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-y/']Details[/URL] [CENTER][IMG]https://ci4.googleusercontent.com/proxy/rGWBborI0k52_MsDZJy_RaNN-mdYO9kn8nF6Ja59CQjaAPx9KFd1-OjG2_wxWCP64E46Mz2WTifUYp7kLgI7g1kHdZKwTziWIRGyQiKyIswnBOFpnKcL_VIv8dvs7giuPWGuOo1MKrAejAwXMtDmbA0YGr31Gg8=s0-d-e1-ft#http://i6.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Cybin[/B] ($CYBN) announced first patient dosing in their Phase I/IIa trial evaluating CYB003, a proprietary deuterated psilocybin analog, as a potential treatment for major depressive disorder. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-j/']Press Release[/URL] [CENTER][IMG]https://ci3.googleusercontent.com/proxy/wCR1TsLXduH1tN1BaBgyxyHPEMrmsVEZOYY5J4zQHv8Y_MwdNGaM7i0YXsVg_Xh8Ozq4-e8yFKzEkf5cC_EYPItWUQbJGt_tPBBF875WK77xVGRiDvqfDGk9OpZoJ20qbrsXKTXn6YkGMb0TJoVHBRB2u_1Qo-g=s0-d-e1-ft#http://i7.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Lobe Sciences[/B] ($LOBE | $LOBEF) entered into an investment agreement with Cantheon Capital to fund $1.5M USD toward clinical trials in Australia. Lobe Sciences will conduct three clinical trials evaluating their proprietary psilocin analogues. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-t/']Press Release[/URL] [CENTER][IMG]https://ci6.googleusercontent.com/proxy/8qHKmKFT2gxFpCbcYiz0CUAMvQQAtW-7qzKtjEBcLp51A4GdxadI3xkh5bCxCmaawDssLLSngjkAYfRYXdXT-0pVjDfvZQvbaIdBIvMWTES14MKVCFbiN2V0htcgubCSOb3XUyM49gcQrAbev_PsyMkDvku1nro=s0-d-e1-ft#http://i8.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Optimi Health[/B] ($OPTI | $OPTHF) entered into an international psilocybin supply agreement with Promises Innovative Recovery, a research and educational center focused on innovative treatments with psychedelic-assisted psychotherapy. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-i/']Press Release[/URL] [CENTER][IMG]https://ci4.googleusercontent.com/proxy/n-vzdQxYgBoGkhwCYpxLNJcwW8pXYBBuyGcNWPl-hP9fXyqE3nGz8E0f78EpXBz-nvjp994pxFyEm5XnS2QKYCeCI4OBJuPFxS5omLOTm0qc_Rn0Z4uMSLWHyBrZaVDcXdHRqI9LWRhTW4u1z3jQdXF-SU7GJ-U=s0-d-e1-ft#http://i9.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Filament Health[/B] ($FH | $FLHLF) began dosing patients with their natural psilocybin drug candidate in a Health Canada-approved clinical trial as part of ATMA Journey Centers' psychedelic-assisted therapist training program. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-d/']Press Release[/URL] [CENTER][IMG]https://ci3.googleusercontent.com/proxy/ViDe4d4DPnjpV4QKzLYZZiJyJziHnnd8YZXlZfKgqb1XcrR7YznxZTd-tUJw9lc9YPTa4oKmRpoCFP11D9123CcPYDGCVfr9b6o7XElOFvx5cU2dp0_neGWVOe3cTHARiAgVqh_TbTGQjsFYYFwLJD14V-rTZvAC=s0-d-e1-ft#http://i10.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Mindset Pharma[/B] ($MSET | $MSSTF) identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds, further expanding their IP portfolio. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-h/']Press Release[/URL] [CENTER][IMG]https://ci6.googleusercontent.com/proxy/u0p8VGgBDzEFwZh5VF6Ry0LdfGjxFOj5DKNWeWjK0XrN_1BwcEoJ6j121dEjjD5ZqVnIPZ2ZEMFoYJhAWWhCgQl5XoyLa_24PEPlTJkE_rKTt9jmA4F7XqSo95tV2JSYJ4NS1X6GBhYeUFQYsHRyInf-rjR2SCU=s0-d-e1-ft#http://i1.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Core One Labs[/B] ($COOL | $CLABF) initiated rollout of their commercial sales strategy for their proprietary biosynthetic API psilocybin product. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-k/']Press Release[/URL] [CENTER][IMG]https://ci6.googleusercontent.com/proxy/Y8hSoxVJyUeR1G9PbXXkiTicdoMPTSnFrpyz4cvpKpIDNV99eBiCL1jRvlJ9sBpdJWqSS_Euof81Fa21Kq8Vv063CegikJ9o73Sqt1p4t5kZuOX-WEhmx2uubcqLqGdav6w6L4C6nY14RMJ0mjLVpP4Dlc_qbu8=s0-d-e1-ft#http://i2.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Wesana[/B] [B]Health [/B]($WESA | $WSNAF) announced the sale of their clinic management assets for USD$2,100,000 as part of an effort to strengthen their balance sheet and streamline the company. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-u/']Press Release[/URL] [CENTER][IMG]https://ci4.googleusercontent.com/proxy/vKk6jzatrDgGyml5QYVy9bMSbLVUu62n3nTg4zNM9evMrBPdg9zKnCyaPOQ0c3CKV4nHVQY8_7QZQwmY3jjlcttdU5-5cIkAHHSEedFm5hjDGEz0T_esWl50tqhdNKXhSGnId1yK68yLuYGzkJm_iT2IqQpg_ho=s0-d-e1-ft#http://i3.cmail20.com/ei/y/04/1BC/116/063955/csfinal/divider-1px-transparent111-990000079e04513c.png[/IMG][/CENTER] [B]Mydecine Innovations [/B]($MYCO | $MYCOF) signed a LOI to sell its wholly-owned subsidiary, Mindleap Health, to PanGenomic Health for a purchase price of C$4,000,000. [URL='https://marketing.cnvsdigital.io/t/y-l-neiya-iutdthhyui-o/']Press Release[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
Psilocybin therapy is effective for treatment-resistant depression
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top